Shanghai MicroPort Endovascular MedTech(Group)Co.,Ltd. News

Heart Care (688016): Securities Research Report/Company Review

Jul 16 00:00

Heart Care (688016): Strong performance growth, overseas mergers and acquisitions help global strategies

Jul 2 12:47

Heart Care (688016): Performance maintains rapid growth, overseas mergers and acquisitions enhance global competitive strength

Jul 2 00:00

Heart Care (688016): Rapid performance growth in the first half of the year, acquisition of high-quality assets accelerated overseas expansion

Jul 1 00:00

Heart Care (688016): Performance maintains high growth and global development accelerates

Jun 3 20:11

Heart Care (688016): First-quarter profits exceeded expectations, and cost control accelerated markedly

May 4 00:00

Heart Care (688016): Profit side growth exceeds expectations and is optimistic about the release of innovative products

May 2 00:00

Heart Care (688016): Revenue growth is in line with expectations, and profit margins have increased due to multiple factors

Apr 28 19:31

Heart Care (688016): Performance is in line with expectations, overseas revenue continues to grow rapidly

Apr 10 19:06

Caixin Securities released a research report on April 9 stating that it gave Cardiac Healthcare (688016.SH) a purchase rating. The main reasons for the rating include: 1) achieving steady growth in aortic stents and rapid release of intraoperative stents

Zhitong FinanceApr 9 15:09

Cardiac Medicine (688016): Aortic Interventions Leading Peripheral Interventions, Rising Performance Growth

Apr 8 00:00

Cardiac Healthcare (688016): 2023 performance is in line with expectations, R&D is progressing smoothly

Apr 3 16:41

Cardiac Healthcare (688016): Steady performance, peripheral products are expected to continue to be approved

Mar 31 00:00

Heart Care (688016): Performance growth slightly exceeds expectations, domestic in-depth channels+overseas markets continue to develop innovative products and accelerate the release of innovative products

Mar 29 07:16

Cardiac Healthcare (688016): Performance achieved rapid growth and progressed steadily in the research pipeline

Mar 29 00:00

Cardiac Healthcare (688016): Resilience in performance highlights outstanding overseas performance

Mar 28 19:41

Heart Care (688016): High growth in 2023 to achieve product penetration and iterative guarantee growth sustainability

Mar 28 18:21

Cardiovascular Medicine (688016): Leading aortic intervention performance continues to increase

Mar 27 00:00

Heart Care (688016) Company Review: New Product Admission Promotion Rapid R&D Pipeline Advances Smoothly

Mar 27 00:00

Cardiovascular Medicine (688016): Aortic intervention leading peripheral products have entered a concentrated harvest period

Mar 26 16:16